^
Association details:
Evidence:
Evidence Level:
Resistant: A2 - Guideline
New
Source:
Excerpt:
The data in the second-line setting suggest that PD-1/PD-L1 monotherapy is less effective irrespective of PD-L1 expression in EGFR+/ALK+ NSCLC.